• COAG share price: currently unavailable. Sorry, we currently don't have enough data to create an insight.

  • Price change

    The price of COAG shares has decreased $2.51 since the market last closed. This is a 5.31% drop.

  • Closed at $44.75.

    The stock has remained unchanged in after-hours trading.

Key terms

About COAG

Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company. It engages in developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. The company was founded on February 12, 2026 and is headquartered in Cambridge, MA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
  • Market cap: $2.09B

    A market capitalization between $2 billion and $10 billion places COAG in the mid-capitalization category.

Key terms

Smart score

Latest COAG news

Jul 14, 2026 8:55am ET Hemab Therapeutics: Strong HMB-002 Data Drive Higher Probability of Success and Lift Price Target from $36 to $46 with Buy Rating by TipRanks Jul 14, 2026 7:50am ET Hemab Therapeutics presents sutacimig data at ISTH Congress by TipRanks Jul 13, 2026 2:50pm ET Analysts Are Bullish on Top NA Stocks: HawkEye 360, Inc. (HAWK), SpaceX (SPCX) by TipRanks Jul 13, 2026 8:55am ET Hemab Therapeutics price target raised to $47 from $39 at Jefferies by TipRanks Jul 13, 2026 8:10am ET Hemab Therapeutics price target raised to $55 from $42 at Wedbush by TipRanks Jul 13, 2026 6:11am ET Hemab Therapeutics price target raised to $52 from $40 at H.C. Wainwright by TipRanks Jul 12, 2026 9:45am ET Hemab Therapeutics presents new clinical data from HMB-002 in VWD by TipRanks Jun 30, 2026 6:26am ET Hemab Therapeutics Holdings, Inc. (COAG) Receives a Buy from Wedbush by TipRanks Jun 26, 2026 12:45pm ET Hemab Therapeutics: Advancing Pipeline, Regulatory Momentum, and Solid Cash Runway Support Buy Rating with Unchanged $40 Price Target by TipRanks Jun 17, 2026 10:06pm ET Major Investor Quietly Ramps Up Stake in Hemab Therapeutics by TipRanks Jun 08, 2026 2:05pm ET Jefferies Reiterates Buy on Hemab Therapeutics, Maintains $39 Price Target on VWD Opportunity and Differentiated Mechanism by TipRanks Jun 08, 2026 2:00pm ET Jefferies sees positive readthroughs to Hemab Therapeutics from Incyte deal by TipRanks May 26, 2026 12:06pm ET Opening Day: SpaceX submits S-1 for Nasdaq IPO by TipRanks May 26, 2026 10:53am ET Hemab Therapeutics initiated with an Outperform at Evercore ISI by TipRanks May 26, 2026 10:22am ET Wedbush bullish on Hemab Therapeutics, initiates with an Outperform by TipRanks May 26, 2026 8:08am ET Hemab Therapeutics initiated with an Outperform at Wedbush by TipRanks May 26, 2026 5:15am ET Hemab Therapeutics initiated with a Buy at Jefferies by TipRanks May 26, 2026 4:25am ET Hemab Therapeutics initiated with a Buy at Goldman Sachs by TipRanks May 26, 2026 2:55am ET Analyst Initiates Buy on Hemab, Citing Differentiated Bleeding-Disorder Pipeline and Multi‑Billion‑Dollar Peak Sales Potential by TipRanks May 21, 2026 10:12pm ET Major Investor Quietly Ups Bet on Hemab Therapeutics in Fresh Stock Move by TipRanks May 14, 2026 10:11pm ET Major Investor Quietly Ramps Up Stake in Hemab Therapeutics by TipRanks May 11, 2026 10:09pm ET Major Investor Quietly Makes a Power Move on Hemab Therapeutics Stock by TipRanks May 06, 2026 10:06pm ET Power Player Makes Bold Insider Bet on Hemab Therapeutics by TipRanks May 04, 2026 11:51am ET Opening Day: Pershing Square listings open soft in market debut by TipRanks May 01, 2026 12:35pm ET Hemab Therapeutics opens at $27, IPO priced at $18 per share by TipRanks Apr 30, 2026 7:05pm ET Hemab Therapeutics 16.75M share IPO priced at $18.00 by TipRanks Apr 30, 2026 2:57pm ET Hemab Therapeutics 15M share IPO price range $16.00-$18.00 by TipRanks
Jul 14, 2026 7:45am ET Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress by GlobeNewswire Jul 12, 2026 6:28am ET Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress by GlobeNewswire Jun 26, 2026 9:00am ET Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the ISTH 2026 Congress by GlobeNewswire May 27, 2026 8:00am ET Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference by GlobeNewswire May 21, 2026 7:00am ET Hemab Therapeutics Reports First Quarter 2026 Financial Results by GlobeNewswire May 04, 2026 4:01pm ET Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares by GlobeNewswire Apr 30, 2026 6:55pm ET Hemab Therapeutics Announces Pricing of Upsized Initial Public Offering by GlobeNewswire

COAG Financials

1-year income & revenue

  • COAG total_revenue: currently unavailable. Sorry, we currently don't have enough data to create an insight.

  • COAG net income: currently unavailable. Sorry, we currently don't have enough data to create an insight.

  • COAG earnings per share: currently unavailable. Sorry, we currently don't have enough data to create an insight.

Key terms

COAG Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

COAG Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range
  • How competitors are chosen

    COAG's competitors are included in the Health Technology sector and Biotechnology group

  • Market cap: $2.09B

    A market capitalization between $2 billion and $10 billion places COAG in the mid-capitalization category.

Key terms

Latest investing news